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Abstract: Oxidative stress has been associated with many diseases as well as aging.
Electrolyzed-reduced water (ERW) has been suggested to reduce oxidative stress and improve
antioxidant potential. This study investigated the effects of drinking ERW on biomarkers of oxidative
stress and health-related indices in healthy adults. We conducted a randomized, double-blind,
placebo-controlled clinical trial on 65 participants, who were allocated into two groups. Of these,
61 received intervention (32 with ERW and 29 MW [mineral water]). All participants were instructed
to drink 1.5 L/day of ERW or MW for eight weeks. Biomarkers of oxidative stress and health-related
indices were assessed at baseline as well as after 4 weeks and 8 weeks of intervention. Of the
primary outcome variables assessed, diacron-reactive oxygen metabolites (d-ROMs) and biological
antioxidant potential showed a significant interaction between the groups and time, with d-ROMs
levels significantly decreased at 8 weeks in ERW compared to those in MW. Among the secondary
outcome variables, total, visceral, and subcutaneous fat mass significantly changed over time, with a
significant association observed between the group and time. Thus, daily ERW consumption may
be a potential consideration for a sustainable and innovatively simple lifestyle modification at the
workplace to reduce oxidative stress, increase antioxidant potential, and decrease fat mass.
Keywords: oxidative stress; electrolyzed-reduced water; biomarkers of oxidative stress; reactive
oxygen metabolites; biological antioxidant potential; fat mass; lifestyle modification
1. Introduction
Free radicals were first described in 1950 [1] and refer to highly unstable and reactive atoms
or molecules, owing to unpaired electrons found in their outer orbit [2]. Reactive oxygen species
(ROS) include reactive nonradical derivatives of oxygen in addition to oxygen-centered radicals [2].
Reactive species are produced not only by natural biological processes but are also generated in
response to external stimuli, such as air pollution, ultraviolet (UV) radiation, infections, inflammation,
heavy metals, cigarette smoking, drugs, strenuous exercise, and emotional stress [3,4]. Oxidative
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stress [5] generated from a disturbance in the balance between the formation and removal of reactive
species has been shown to result in oxidative damage to various macromolecules, such as lipids,
DNA, and proteins [2,5–8], and have been implicated as an etiological agent in many pathologic
processes including aging [2,6,9,10], radiation injury, cardiovascular disease, diabetes, atherosclerosis,
neurological diseases, and cancers [3]. Endogenous antioxidant defense mechanisms act together
with exogenous antioxidants to prevent oxidative damage. Our body has an endogenous defense
mechanism, including enzymatic and non-enzymatic systems, to counteract oxidative stress. Hence,
diverse strategies exist for estimating oxidative stress status, including detection of free radicals, ROS,
damaged macromolecules from oxidative stress, antioxidant capacity, and antioxidant enzymes for
antioxidant potential, as well as health-related indices for altered medical conditions resulting from
oxidative stress [7,11].
Electrolyzed-reduced water (ERW) is produced near the cathode during water electrolysis [12].
Accordingly, ERW has been shown to be rich in hydrogen atoms and hydrogen molecules, low in
dissolved oxygen, with an alkaline pH, and has negative oxidation-reduction potential (ORP) [13,14].
An increasing number of studies have been conducted on alkaline and ERW since the effectiveness of
ERW at scavenging ROS in vitro as well as its ability to protect against oxidative stress-induced DNA
damage [15].
ERW has been shown to suppress oxidative stress by improving the function of antioxidant enzymes
in U937 cell line [16], protect neural cells from oxidative damage [17], inhibit tumor angiogenesis [18],
enhance apoptosis of leukemia cells (HL-60) [12,19], shorten cancer cell telomeres [14,20], and suppress
invasion of human fibrosarcoma HT-1080 cells [21]. There was also a noteworthy study after the
Fukushima disaster in 2011, suggesting that radionuclides, such as cesium and iodine could be
removed by an ERW-producing apparatus [22]. In animal studies, ERW was effective in lowering
the levels of blood glucose in both type 1 and type 2 diabetic mice models [23], lowering plasma
triglycerides levels and suppressing lipid peroxidation levels [24], reducing lipopolysaccharide
(LPS)-induced neuroinflammation [25], demonstrating neuroprotection in cisplatin-induced kidney
damage and improving oxidative stress biomarker levels [26], as well as prolonging the lifespan
of nematodes [27] and mice [28]. Similarly, ERW was reported to reduce oxidative stress [29] and
erythrocyte impairment [30] while improving T-cell damage [31] in patients with end-stage renal
disease undergoing hemodialysis.
Meanwhile, natural reduced water found in various natural environments, such as deep
underground reservoirs and springs, and known to scavenge ROS [12], has been reported to inhibit
alloxan-induced β-cell apoptosis [32], lower glucose levels in alloxan-induced mice [32], suppress
anxiety in rats [33], and increase the activity of natural killer cells in healthy volunteers [34]. Moreover,
drinking alkaline MW was shown to lower the bone resorption marker in adults with sufficient
calcium [35] and to significantly decrease the concentration of lactic acid at rest in patients in a clinical
trial [36]. In an open-label pilot study, consumption of hydrogen-rich water supplemented with a
mineral stick improved indices related to oxidative stress and metabolic syndrome [37].
Health promotion programs adopting lifestyle modifications at the workplace are being
implemented in several countries [38]. Several randomized clinical trials have been conducted
to assess the effects of these healthy behaviors at the workplace, some of which reported meeting
their primary endpoint, while others did not [39–42]. Nevertheless, these trials have raised questions
regarding issues related to sustainability, affordability, and cost-effectiveness in terms of public and
planetary health [38,43]. Daily consumption of water with improved function in the workplace may
elicit a more positive effect on health promotion. However, an insufficient number of randomized,
double-blinded, placebo-controlled clinical trials have investigated the effects of drinking ERW on
healthy workers’ oxidative stress levels and related health. Therefore, the objective of this study was
to assess the effects of sustainable and innovatively simple lifestyle modification at the workplace,
namely drinking ERW for eight weeks, on biomarkers of oxidative stress and health-related indices in
healthy adults.
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2. Materials and Methods
2.1. Overview of the Study Design
We conducted a single-center, double-blind, placebo-controlled, parallel-group study in South
Korea, in accordance with the “Ethical principles for medical research involving human subjects”
defined in the declaration of Helsinki in 1975 (last updated in 2018), and following the Consolidated
Standards of Reporting Trials (CONSORT) guidelines. The institutional review board of Bundang
Jesaeng Hospital in Korea approved the study (IRB DMC 2018-11-009), and all subjects provided
informed consent prior to participation. The study was registered at the Clinical Research Information
Service-Republic of Korea (CRIS, https://cris.nih.go.kr/cris/) on 18 April 2019 (CRIS Registration Number
KCT0003808) and was conducted between February 2019 and May 2019.
2.2. Participants, Eligibility Criteria, and Recruitment
The inclusion criteria for our study were: (1) subjects who voluntarily agreed to participate and
signed informed consent, and (2) healthy volunteers between the ages of 18 and 65 years old (including
patients with controlled hypertension or diabetes mellitus). The exclusion criteria were as follows:
(1) smokers; (2) alcohol consumption greater than 4 regular (250 cc) cups of beer, or 5 small (50 cc)
glasses of Korean distilled spirits per day for men, and 2 regular (250 cc) cups of beer, or 2.5 small
(50 cc) glasses of Korean distilled spirit per day for women, or drinking for more than two times per
week; (3) pregnant women; (4) uncontrolled diabetes mellitus; (5) uncontrolled high blood pressure;
(6) subjects with implanted cardiac pacemaker; (7) subjects taking antioxidant supplements, such as
vitamin C, vitamin E, flavonoids, bilberry, CoQ19, glutathione, omega-3, Mg, Mn, and Zn (2 weeks of
washout period was required before enrollment). Subjects were recruited through an announcement
posted on a bulletin board inside Bundang Jesaeng Hospital in Korea between 30 January 2019 and
19 February 2019.
2.3. Study Setting and Interventions
This study was conducted at Bundang Jesaeng Hospital in Seongnam, South Korea, from February 2019
to May 2019. Five ERW-producing apparatus sets (AML 3010S, Alkamedi Co. Ltd., Anyang, Korea)
were installed at five different locations throughout the hospital (OASIS-O area, OASIS-A area,
OASIS-S1 area, OASIS-S2 area, and OASIS-I area). Each installed device consisted of two units.
The first was a carbon filter unit that purified tap water for production of MW, whereas the second
was an electrolysis unit consisting of five platinum (Pt)-coated titanium (Ti) electrode plates separated
by semipermeable membranes for producing ERW [17,22]. Purified MW flows into the electrolysis
unit, where it becomes electrolyzed while passing through the gap between the Pt-Ti electrodes [22].
ERW containing hydrogen (H2) gas and hydroxide ions (OH−) are produced at the cathode [12],
whereas electrolyzed oxidized water containing oxygen (O2) gas and hydrogen ions (H+) are produced
at the anode [12] by electrolysis of water. ERW produced by electrolysis devices generally exhibits
high pH, low ORP, and high dissolved hydrogen [12,13,22]. In this study, the pH, ORP, dissolved
hydrogen concentration, and electric conductivity of the ERW-producing apparatus were 9.39 ± 7.2,
−111.36 ± 7.39 mV, 586.8 ± 20.5 µg/L, and 273.6 ± 0.52 µS/cm, respectively, whereas those for the
MW-producing apparatus were 7.2 ± 0.1, 304.00 ± 6.74 mV, 0.00 ± 0.00 µg/L, and 273.5 ± 0.53 µS/cm,
respectively. Additionally, the source tap water used in the study was distributed by Bokjeong Water
Purification Plant, Seongnam, South Korea and had been demonstrated to be suitable for drinking
based on the quality analysis conducted by the engineer of the department of Clean Water Management
Office in Seongnam City Hall. Analysis of the tap water showed a pH of 7.5, residual chlorine level of
0.12 mg/L, turbidity of 0.06 NTU, Cu level of 0.017 mg/L, Fe level of < 0.3 mg/L, and nondetectable
levels of Zn and Mn. However, the limited elemental profile analysis performed for both ERW and
MW might have hindered a further thorough chemical comparison of these waters in the current study.
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Sixty-five participants were allocated into two groups; of these, 61 received intervention (32 for
ERW and 29 for MW) while the remaining four voluntarily withdrew prior to commencement of the
study. Participants were supplied with bottles of the same shape and size. However, bottles were of
two different colors (blue or green), were able to hold 750 cc of water, and participants were instructed
to drink 1.5 L/day of water from the devices allocated to their group for eight weeks.
2.4. Outcome Variables
The primary outcome of our study was to evaluate oxidative stress biomarkers including
measurement of serum biological antioxidant potential (BAP), diacron-reactive oxygen metabolites
(d-ROMs), oxidized low-density lipoprotein (oxLDL), superoxide dismutase (SOD), and catalase (CAT)
levels; urine malondialdehyde (MDA) and 8-hydroxydeoxyguanosine (8-OHdG) levels; and plasma
glutathione peroxidase (GPx) levels. OxLDL, a parameter of protein oxidation, was added after the
study commenced to estimate the oxidative stress in more diverse aspects. The secondary outcome
was to evaluate health-related indices, including the biochemistry profile (aspartate aminotransferase
(AST), alanine aminotransferase (ALT), low-density lipoprotein (LDL) cholesterol, triglyceride, glucose,
insulin, homeostatic model assessment for insulin resistance (HOMA-IR), cortisol, total bilirubin,
gamma-glutamyltransferase (GGT), uric acid, lactic acid, alkaline phosphatase (ALP), serum calcium,
urine calcium), natural killer (NK) cell activity, advanced glycation end product (AGE) of skin, fat mass
(total, visceral, and subcutaneous), cardio-ankle vascular index (CAVI), heart rate variability (HRV),
whole-body phase angle (PhA), as well as implementation of questionnaires to assess stress (Brief
Encounter Psychosocial Instrument-Korean version (BEPSI-K)), fatigue (Brief Fatigue Inventory (BFI)
and Fatigue Severity Scale (FSS)), and Health-Related Quality of Life (HRQoL) (36-Item Short Form
Survey (SF-36)). Primary and secondary outcome variables were assessed at baseline as well as after
4 weeks and 8 weeks of intervention.
2.5. Sample Size
The sample size was determined using the G Power 3.1 program [44]. Considering that few
randomized controlled trials (RCT) have been performed to offer appropriate effect size for similar
primary outcomes, Cohen’s convention for effect size (Cohen 1977) was applied, assuming detection
of a medium effect (f = 0.25). Further, results from the Priori power analysis conducted to test the
within-between interactions using repeated measured ANOVA with a medium effect size (f = 0.25),
and an alpha of 0.05, determined that a total sample size of 42 participants with two equal-sized groups
(n = 21) was required to achieve a power of 0.95 [44]. However, considering the potential dropout rate





where N = adjusted sample size, n = sample size required as per G power, and d = dropout rate [45,46].
2.6. Randomization, Allocation, and Blinding
Randomization was conducted by an independent investigator not otherwise involved in the
clinical trial using the R package 3.5.2. (2018, The R Foundation for Statistical Computing) [47].
Accordingly, a 1:1 allocation to the green or blue group was accomplished using permuted block
randomization with random block sizes of 4, 6, and 8. The allocation sequence was concealed in
an opaque, sealed envelope, and provided to the research manager. The envelope was concealed
until all enrolled subjects had provided informed consent and baseline assessments were completed.
The research manager opened the envelope and assigned participants to the two groups according to
the allocation sequence, while bottles of two different colors (blue or green) for drinking water were
distributed to all participants.
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The pH of the water in each electrolysis apparatus (ten apparatuses, five for ERW group, and five
for MW group) was defined outside the hospital, before installation. Until the analysis of data, the pH
of the water in each apparatus was blinded to investigators, participants, and the research manager by
turning off the light of the LCD monitor on the surface of the apparatus, which otherwise showed the
pH of the water in real-time. Meanwhile, a photo of each bottle (blue or green) pertaining to ERW or
MW was attached on the surface of each apparatus by the engineer of the company who installed the
apparatus. The bottle color for either the ERW or MW group was blinded to investigators, participants,
and the research manager until the completion and analysis of the study. The participants assigned to
the two groups were instructed to drink water from the apparatus on which the photo of the bottle of
the same color with their group name was attached.
2.7. Measurement of Outcome Variables
After overnight fasting for 12 h, blood was collected from a vein in the cubital fossa using a BD
vacutainer system (Becton Dickenson, Plymouth, UK) into 1 cc Promoca™ (for the activity of NK cells),
3 cc heparin (for lactic acid), 3 cc EDTA (for GPx and complete blood count (CBC) with differentials),
and 8.5 cc SST (for other parameters) tubes. Urine samples were collected into 10 cc simple urine tubes
(for urine Ca, thiobarbituric acid reactive substances (TBARS), and 8-OHdG).
Blood in SST tubes was allowed to clot at 25 ◦C for approximately 15 min and then centrifuged
(Kubota 4000, Kubota corp., Tokyo, Japan) at 1710× g for 10 min. Tubes containing EDTA as anticoagulant
were centrifuged at 430× g for 10 min to obtain plasma. A portion of the serum and plasma sample
supernatants were pipetted into microtubes and stored at −80 ◦C until analysis. Urine samples
were processed in the same way if immediate analysis was not available. Serum SOD, CAT, oxLDL,
plasma GPx, urine TBARS, and 8-OHdG were analyzed at GC Labs (Yongin, South Korea), while NK
cells activity was analyzed at ATGEN (Seongnam, South Korea). All other samples were analyzed at
the Department of Laboratory Medicine, Bundang Jesaeng Hospital (Seongnam, South Korea).
2.7.1. Biomarkers of Oxidative Stress
The d-ROMs and BAP test were performed according to the manufacturer’s instructions (Wismerll,
Tokyo, Japan). The d-ROMs test evaluates the status of oxidative stress by determining hydroperoxides
(ROOH) and diverse organic compounds (lipids, proteins, nucleic acids, etc.) levels [48] through
detection of chromogenic substrate (N,N-diethyl-para-phenylenediamine) oxidation by radicals
converted from hydroperoxides [49,50]. The reaction is photometrically monitored at 505 nm,
and results are expressed as Carratelli Units (U.CARR), where 1 U.CARR corresponds to 0.8 mg/L
H2O2. The standard reference level for d-ROMs was 250-300 U.CARR [51,52]. The BAP test provides a
global measurement of many antioxidants, including uric acid, ascorbic acid, and bilirubin [53,54],
based on the ability of a blood sample to reduce ferric ions to ferrous ions [53–55]. Urine MDA was
measured using an enzyme-linked immunosorbent assay (ELISA) and the OxiSelect™ TBARS assay
kit (Cell Biolabs, San Diego, CA, USA) according to the manufacturer’s instructions. The TBARS has
been used as a tool for direct quantitative measurement of MDA [56]. Urine 8-OHdG was assessed by
competitive ELISA using the “8-OHdG check” kit (JaICA, Fukuroi City, Japan) based on a monoclonal
antibody specific for quantification of 8-OHdG [57,58]. Oxidized low-density lipoprotein (oxLDL)
was determined using the Mercodia oxLDL ELISA kit (Mercodia, Uppsala, Sweden) according to
manufacturer’s instruction [58]. All enzymatic activities were evaluated using assay kits (Cayman
Chemicals, Ann Arbor, MI, USA) following the manufacturer’s instructions [59,60]. The absorbance
of MDA, 8-OHdG, oxLDL, and GPx were measured colorimetrically at 532 nm, 450 nm, 450 nm,
and 340 nm respectively, using an ELISA microplate reader (VersaMax, Molecular Devices, San Jose,
CA, USA) [56–60].
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2.7.2. Biochemistry Parameters
The CBC was measured with an Advia 2120 (Siemens Healthcare Diagnostics, Erlangen, Germany),
while the neutrophil to lymphocyte ratio (NLR) was calculated by dividing the absolute neutrophil
count by the absolute lymphocyte count [61]. The levels of HbA1c were measured using an HLC-723®
G11 glycohemoglobin (HbA1c) automated analyzer (Tosho Co., Ltd., Tokyo, Japan) employing
high-performance liquid chromatography. The levels of insulin and cortisol were measured using
electro-chemiluminescence immunoassays (ECLIA) in a Cobas 8000-E602 module biochemistry analyzer
(Roche Diagnostics, Basel, Switzerland), according to the standard operating procedures recommended
by the manufacturer. We calculated HOMA-IR using the standard formula based on fasting glucose
and insulin [54], according to Equation (2) [62]:
HOMA− IR =












Other biochemistry parameters were measured using the TBA2000FR automated chemistry
analyzer (Toshiba, Tokyo, Japan) according to standard methods.
2.7.3. Activity of NK Cells
The activity of natural killer cells was measured using the NK Vue™ kit (ATgen, Sungnam, Korea)
according to the manufacturer’s instructions. This kit uses an immunomodulatory cytokine (Promoca)
to stimulate NK cells in whole blood. The level of secreted interferon (IFN) is then determined using
ELISA [63]. Absorbance was measured at 450 nm using a microplate reader (SpectraMax 190, Molecular
Devices, LLC., San Jose, CA, USA).
2.7.4. Advanced Glycation End Products (AGEs)
The AGEs were determined using an AGE Reader (DiagnOptics, Groningen, Netherlands),
as previously described. The device illuminates a skin surface [64] using an excitation light source
with a wavelength between 300 nm and 420 nm. Skin emits light at a wavelength range of 420–600 nm.
Skin autofluorescence was then measured by calculating the ratio of the average reflected light
intensity to the average emitted light intensity multiplied by 100 and was expressed in arbitrary units
(AU) [65,66].
2.7.5. Cardio-Ankle Vascular Index (CAVI)
The CAVI, used for assessment of arterial stiffness [67], was measured using the VASERA
VS-1000 automatic pulse wave analyzer (Fukuda Denshi Co. Ltd., Tokyo, Japan) as previously
described [62,68]. The arterial pressure waveforms of the brachial and ankle arteries, phonocardiography,
and electrography were measured, and CAVI was automatically calculated by the analyzer [69–71].
2.7.6. Heart Rate Variability (HRV)
Parameters of HRV, including the time and frequency domains monitoring the balance and activity
of the autonomic nervous system, were analyzed using the SA-6000 heart rate variability analysis
system (Medicore Co.,Ltd., Seoul, Korea) according to the manufacturer’s instructions [72,73]. The time
domain parameters analyzed were the mean heart rate, standard deviation of the N-N interval (SDNN),
square root of the mean squared differences of successive N-N intervals (RMSSD), and physical stress
index (PSI), whereas the frequency domain parameters analyzed were the total (TP), low frequency
(LF), and high frequency (HF) power. The ratio of the low frequency to high frequency (LF/HF ratio)
was then calculated [72,73].
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2.7.7. PhA and Body Composition
PhA was measured using the InBody S10 multifrequency bioelectrical impedance analyzer
(InBody, Seoul, Korea) [74]. The extracellular water (ECW), total body water (TBW), reactance (Xc),
and impedance (Z) of right arm (RA), right leg (RL), left arm (LA), left leg (LL), and trunk were
recorded [75]. PhA was calculated from reactance (Xc) and impedance (Z) (measured at 50 kHz) using
Equation (3):







Total PhA was calculated according to Equation (4) measured at 50 kHz:
Total PhA (◦) = arcsin
(
sum o f Xc o f (RA + RL + TR)
sum o f R o f (RA + RL + TR)
)
(4)
Overall body composition was measured using the X-SCAN PLUS 950 body composition analyzer
(Selvas Healthcare, Daejun, Korea) in which body weight, height, body mass index (BMI), fat mass,
visceral fat mass, and subcutaneous fat mass were measured.
2.7.8. Blood Pressure and Pulse Rate
Blood pressure and pulse rate were measured using the BPBIO320 single-cuff oscillometer blood
pressure (BP) monitor (Inbody, Seoul, Korea).
2.7.9. Questionnaires to Evaluate Stress, Fatigue, and HRQoL
The BEPSI-K [76,77] was used to measure stress levels. Concomitantly, perceived fatigue was assessed
using the validated BFI [78] and FSS [79]. The HRQoL was measured using the SF-36 questionnaire [80].
2.8. Data Analysis
Data were analyzed using the IBM SPSS Statistics for Windows Software (Version 22.0, Armonk,
NY, USA). The values presented in the text were expressed as means (M) ± standard deviation
(SD). The normality of the distribution of variables was evaluated using the Shapiro-Wilk test.
When comparing the continuous variables between the ERW and MW groups at baseline, the Student’s
t-test or the Mann-Whitney U test was used. For categorical response variables, the differences
between the two groups were assessed using the Pearson’s Chi-squared test, Fisher’s exact test,
or linear-by-linear association. To determine differences between groups over time, analysis of variance
with repeated measures with the post hoc Bonferroni adjustment for multiple comparisons was
performed. Results were considered to be significant at p < 0.05.
3. Results
Initially, 81 subjects were approached for screening. Of these, 13 declined while 68 consented
to undergo screening, of which two subjects did not meet the inclusion criteria and one refused to
participate in the study. Accordingly, 65 subjects, meeting the inclusion and exclusion criteria, and who
had provided written informed consent, were enrolled in the study and randomly assigned into the
ERW (n = 32) or MW group (n = 33). A total of 61 subjects received the allocated intervention and
underwent 4-week follow-up evaluation, whereas three and five subjects in the ERW and MW group,
respectively, discontinued intervention before 8-week follow-up, owing to their inability to continue
drinking the recommended volume of water. After the scheduled follow-up, 53 subjects, 29 in the ERW
and 24 in the MW group, completed the study and were assessed for primary and secondary outcomes
(per-protocol (PP) analysis) (Figure 1).
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Figure 1. A Consolidated Standards of Reporting Trials (CONSORT) flow diagram.(corrected in the
separate files)
3.1. Baseline Characteristics of Study Participants
Baseline demographic and clinical characteristics of the study participants are presented in Table 1.
No significant differences were observed between the two groups, except for d-ROMs, the p-value of
which was nly slightly below 0.05 (p = 0.046) (Table 1).
3.2. Effect of Treatment on the Pri utcome V riables: Biomarkers of Oxidative Stress
Data were analyzed via repeated measure ANOVA using a within-subject factor of time, and a
between-subject factor of group. The ERW group displayed a reduction in TBARS, 8-OHdG,
and d-ROMs levels (mean ± SD) and an increase in BAP and GPx levels (mean ± SD) from baseline to
4 and 8 weeks follow-up (Table 2 and Supplementary Table S2).
Tabl 1. Baseline charact ristics of study participants.
Characteristic ERW(n = 29)
MW
(n = 24) p-Value
Demograp ic years
Age 39.3 ± 8.9 41.0 ± 9.3 0.523 *
Sex no. (%) 1.000 †
Female 25 (86.2%) 21 (87.5%)
Male 4 (13.8%) 3 (12.5%)
Marital status no. (%) 0.378 ‡
Married 18 (62.1%) 12 (50.0%)
Single 11 (37.9%) 12 (50.0%)
Educational level no. (%) 0.701 §
High school 3 (10.3%) 2 (8.3%)
College/University 21 (72.4%) 17 (70.8%)
Postgraduate 5 (17.2%) 5 (20.8%)
Occupation no. (%) 0.886 §
Professionals 6 (20.7%) 5 (20.8%)
White collar 20 (69.0%) 17 (70.8%)
Blue collar 3 (10.3%) 2 (8.3%)
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Table 1. Cont.
Characteristic ERW(n = 29)
MW
(n = 24) p-Value
Clinical
d-ROMs U.CARR 301.3 ± 68.6 347.3 ± 94.9 0.046 *
BAP umol/L 2027.4 ± 226.9 2015.7 ± 274.8 0.734 ‖
TBARS(MDA) µM 9.88 ± 4.67 8.90 ± 5.98 0.506 *
8-OHdG ng/mL 14.33 ± 6.88 10.90 ± 6.42 0.069 *
oxLDL U/L 52.43 ± 17.38 49.38 ± 13.61 0.520 ‖
GPx nmol/min/mL 151.4 ± 31.1 140.1 ± 34.9 0.180 ‖
Body Mass Index kg/m2 22.2 ± 3.1 23.0 ± 3.1 0.357 *
Blood pressure mmHg
Systolic 116.3 ± 10.6 116.3 ± 9.5 0.943 ‖
Diastolic 72.0 ± 11.6 72.4 ± 9.5 0.971 ‖
Glucose mg/dL 92.8 ± 7.5 92.3 ± 6.9 0.805 *
Note: Continuous variables are represented as means ± standard deviations (SD) and compared by * T test
or ‖ Mann-Whitney U Test. Categorical variables are given as numbers (no) with percentages (%) and
compared by ‡ Pearson’s Chi-Squared Test, † Fisher’s Exact Test, or § Linear-by-Linear Association as appropriate.
Abbreviations: ERW, electrolyzed-reduced water; MW, mineral water; d-ROMs, diacron-reactive oxygen metabolites;
BAP, biological antioxidant potential; TBARS, thiobarbituric acid reactive substances; MDA, malondialdehyde;
8-OHdG, 8-hydroxy-2-desoxyguanosine; oxLDL, oxidized low-density lipoprotein; GPx, glutathione peroxidase.




(n = 24) p
Outcome Variables Means ±SD Means ±SD Time Group Time * Group
d-ROMs(U.CARR)
Baseline 301.3 ± 68.6 347.3 ± 94.9
4 weeks 286.7 ± 45.1 306.3 ± 54.8 0.004 0.007 0.044
8 weeks 288.0 ± 50.0 349.6 ± 62.7
BAP (umol/L)
Baseline 2027.4 ± 226.9 2015.7 ± 274.8
4 weeks 2585.9 ± 258.8 2504.8 ± 187.8 0.000 0.875 0.045
8 weeks 2603.9 ± 255.9 2670.4 ± 180.2
TBARS (MDA) (µM)
Baseline 9.88 ± 4.67 8.90 ± 5.98
4 weeks 6.84 ± 3.99 8.95 ± 6.14 0.003 0.809 0.091
8 weeks 6.97 ± 4.51 6.63 ± 4.47
8-OHdG (ng/mL)
Baseline 14.33 ± 6.88 10.90 ± 6.42
4 weeks 13.87 ± 8.31 15.63 ± 11.18 0.033 0.594 0.138
8 weeks 11.87 ± 7.90 10.87 ± 7.00
oxLDL (U/L)
Baseline 52.43 ± 17.38 49.38 ± 13.61
4 weeks 53.60 ± 15.32 52.00 ± 12.94 0.332 0.679 0.534
8 weeks 52.24 ± 15.97 52.1 ± 12.99
GPx (nmol/min/mL)
Baseline 151.4 ± 31.1 140.1 ± 34.9
4 weeks 162.8 ± 36.5 161.7 ± 37.9 0.000 0.639 0.412
8 weeks 185.8 ± 30.9 189.6 ± 23.6
Note: * Interaction between Time and the Group. Abbreviations: ANOVA, analysis of variance; d-ROMs,
diacron-reactive oxygen metabolites; BAP, biological antioxidant potential; TBARS, thiobarbituric acid reactive
substances; MDA, malondialdehyde; 8-OHdG, 8-hydroxy-2-desoxyguanosine; oxLDL, oxidized low-density
lipoprotein; GPx, glutathione peroxidase.
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The effect of time showed a significant difference in mean d-ROMs levels at different time points,
F(1.68, 85.65) = 6.61, p = 0.004, partial η2 = 0.115; and the main effect of the group displayed a significant
difference in the mean d-ROMs levels between the two groups, F(1, 51) = 8.04, p = 0.007, partial
η2 = 0.136. There was a significant interaction observed between the intervention and time on the
d-ROMs levels, F(1.68, 85.65) = 3.44, p = 0.044, partial η2 = 0.063 (Table 2 and Table S2). Follow-up
assessments were carried out to determine the difference of d-ROMs levels between groups at each
time point and the effect of time on d-ROMs levels in each group. A significant difference was observed
in the serum d-ROMs levels between the two groups at 8 weeks intervention, F(1, 51) = 15.87, p < 0.001,
partial η2 = 0.237; and serum d-ROMs levels were significantly lower in the ERW compared to those
in the MW group (mean difference (Mdiff) = 61.66, standard error (SE) = 15.48 U.CARR, p < 0.001).
There was also a significant effect of time on d-ROMs levels in the MW group, F(1.59, 36.58) = 6.09,
p = 0.005, partial η2 = 0.209. Furthermore, d-ROMs levels were significantly lower at 4 weeks compared
to those at baseline (Mdiff = 41.04, SE = 14.06 U.CARR, p = 0.023).
Mean BAP levels significantly differed between time points, F(2,102) = 258.47, p < 0.001, partial
η2 = 0.835. Regarding the effect of the group, no significant difference was observed in the mean BAP
levels between the two groups, F(1,51) = 0.03, p = 0.875, partial η2 < 0.001. However, a significant
interaction was observed between the group and time on BAP levels, F(2,102) = 3.20, p = 0.045, partial
η2 = 0.059 (Table 2 and Table S2). Follow-up assessments for the effect of each intervention revealed
slightly, yet not significantly, higher BAP levels in the ERW compared to the MW group at 4 weeks,
F(1,51) =1.64, p = 0.206, partial η2 = 0.031. There was a significant effect of time on BAP levels in the
ERW group, F(2,56) = 179.46, p < 0.001, partial η2 = 0.865; as well as in the MW group, F(2,46) = 97.36,
p < 0.001, partial η2 = 0.809. In the ERW group, BAP levels were significantly higher at 4 weeks
than those at baseline (Mdiff = 558.52, SE = 32.40 umol/L, p < 0.001) and at 8 weeks than those at
baseline (Mdiff = 576.45, SE = 38.73 umol/L, p < 0.001). Meanwhile, in the MW group, BAP levels were
significantly higher at 4 weeks (Mdiff = 489.04, SE = 53.66 umol/L, p < 0.001) and 8 weeks (Mdiff = 654.71,
SE = 51.49 umol/L, p < 0.001) than those at baseline and at 8 weeks than those at 4 weeks (Mdiff = 165.67,
SE = 40.14 umol/L, p = 0.001).
Mean TBARS, 8-OHdG, and GPx levels significantly differed between time points (TBARS:
F(2,102) = 6.23, p = 0.003, partial η2 = 0.109; 8-OHdG: F(2,102) = 3.52, p = 0.033, partial η2 = 0.065;
GPx: F(2,102) = 27.07, p < 0.001, partial η2 = 0.347); however, these levels were not significantly different
between the two groups (TBARS: F(1,51) = 0.06, p = 0.809, partial η2 = 0.001; 8-OHdG: F(1,51) = 0.29,
p = 0.594, partial η2 = 0.006; GPx: F(1,51) = 0.22, p = 0.639, partial η2 = 0.004). The interaction between
the group and time did not significantly influence TBARS (F(2,102) = 2.45, p = 0.091, partial η2 = 0.046),
8-OHdG (F(2,102) = 2.02, p = 0.138, partial η2 = 0.038), and GPx (F(2,102) = 0.89, p = 0.412, partial
η2 = 0.017) levels. Mean oxLDL levels did not significantly differ at different time points (F(2,102) = 1.11,
p = 0.332, partial η2 = 0.021) or between the two groups (F(1,51) = 0.17, p = 0.679, partial η2 = 0.003).
The interaction between the group and time did not display a significant effect on mean oxLDL levels
(F(2,102) = 0.63, p = 0.534, partial η2 = 0.012) (Table 2 and Table S2).
3.3. Effect of Treatment on the Secondary Outcome Variables: Biochemistry Parameters
Mean NK cell activity significantly differed between time points, F(2,102) = 20.94, p < 0.001, partial
η2 = 0.291. In contrast, the intervention did not exert a significant effect on mean NK cell activity
between the two groups, F(1,51) = 0.40, p = 0.528, partial η2 = 0.008. The interaction between the
group and time did not significantly influence mean NK cell activity, F(2,102) = 1.26, p = 0.289, partial
η2 = 0.024 (Table 3 and Table S3).
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(n = 24) p
Outcome Variables Means ±SD Means ±SD Time Group Time * Group
NK Cell
Activity(pg/mL)
Baseline 949.0 ± 810.7 1263.4 ± 905.2
4 weeks 1943.5 ± 1109.2 1829.0 ± 1136.7 0.000 0.528 0.289
8 weeks 1814.2 ± 1091.8 2042.0 ± 964.9
Glucose (mg/dL)
Baseline 92.8 ± 7.5 92.3 ± 6.9
4 weeks 92.8 ± 8.2 92.1 ± 6.0 0.978 0.640 0.916
8 weeks 93.0 ± 5.9 91.8 ± 6.2
HbA1c(mg/dL)
Baseline 5.2 ± 0.3 5.3 ± 0.3
4 weeks 5.3 ± 0.3 5.4 ± 0.2 0.000 0.228 0.971
8 weeks 5.3 ± 0.3 5.4 ± 0.3
Insulin (uU/mL)
Baseline 8.65 ± 3.78 8.21 ± 10.31
4 weeks 6.66 ± 3.19 7.18 ± 4.76 0.091 0.729 0.401
8 weeks 7.15 ± 3.19 8.50 ± 6.78
HOMA-IR
Baseline 2.21 ± 0.93 1.95 ± 2.74
4 weeks 1.55 ± 0.80 1.65 ± 1.15 0.112 0.739 0.575
8 weeks 1.68 ± 0.80 1.98 ± 1.61
A.G.E. (AU)
Baseline 2.05 ± 0.26 2.04 ± 0.27
4 weeks 1.83 ± 0.32 1.82 ± 0.23 0.000 0.767 0.246
8 weeks 1.82 ± 0.34 1.91 ± 0.33
Cortisol(ng/mL)
Baseline 80.81 ± 35.53 81.78 ± 25.30
4 weeks 76.95 ± 27.36 79.06 ± 41.63 0.743 0.443 0.308
8 weeks 72.63 ± 27.47 85.70 ± 26.27
Lactic Acid(mmol/L)
Baseline 1.76 ± 0.86 1.52 ± 0.55
4 weeks 1.65 ± 0.65 1.58 ± 0.61 0.454 0.699 0.093
8 weeks 1.44 ± 0.45 1.61 ± 0.47
Note: * Interaction between Time and the Group. Abbreviations: NK, natural killer; HbA1c, glycosylated hemoglobin;
HOMA-IR, homeostatic model assessment for insulin resistance, A.G.E., advanced glycation end products; AU,
arbitrary units.
In both intervention groups, AGE, insulin, HOMA-IR, and cortisol levels were lower at 4 and
8 weeks than those at baseline. Regarding the effect of time, a significant difference was observed in the
mean AGE, F(2,102) = 20.94, p < 0.001, partial η2 = 0.291 at different time points. Regarding variables
other than AGE, the effect of time did not display a significant difference. Similarly, no significant
difference was observed in the effect of the intervention itself. Furthermore, the group and amount of
time did not have an interactive effect on AGE or other biochemical profiles (Table 3 and Table S3).
3.4. Effect of Treatment on the Secondary Outcome Variables: Body Composition, CAVI, HRV, and PhA
Significant interactions between the group and time were observed in total fat mass, F(1.80,91.60)
= 3.43, p = 0.041, partial η2 = 0.063, visceral fat mass, F(2,102) = 3.76, p = 0.027, partial η2 = 0.069,
and subcutaneous fat mass, F(1.78,90.50) = 3.29, p = 0.047, partial η2 = 0.061 (Table 4 and Table S4).
Regarding the effect of time, significant differences were observed in total fat mass, F(1.80,91.60) = 10.12,
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p < 0.001, partial η2 = 0.166, visceral fat mass F(2,102) = 9.96, p < 0.001, partial η2 = 0.163,
and subcutaneous fat mass, F(1.78,90.50) = 9.81, p < 0.001, partial η2 = 0.161, at different time
points (Table 4 and Table S4). Follow-up assessments were performed for fat mass to determine the
differences between the groups at each time point and the effect of time in each group. However,
the intervention itself at 4 and 8 weeks did not significantly influence total, visceral, or subcutaneous
fat mass. Alternatively, the effect of time significantly influenced total fat mass in the MW group,
F(2, 46) = 7.47, p = 0.002, partial η2 = 0.245, but not in the ERW group, F(1.49,41.74) = 2.40, p = 0.116,
partial η2 = 0.079. In the MW group, total fat mass was significantly lower at 8 weeks than at baseline
(Mdiff = 1.208, SE = 0.317 kg, p = 0.003). The effect of time also significantly influenced the visceral fat
mass both in the ERW, F(2,56) = 3.80, p = 0.028, partial η2 = 0.120, and MW, F(2,46) = 7.06, p = 0.002,
partial η2 = 0.235 groups, being significantly lower at 8 weeks than at 4 weeks in the ERW group
(Mdiff = 0.083, SE = 0.028 kg, p = 0.019), and significantly lower at 8 weeks than at baseline in the MW
group (Mdiff = 0.212, SE = 0.058 kg, p = 0.004). However, the effect of time significantly influenced
subcutaneous fat mass in the MW group, F(2,46) = 7.32, p = 0.002, partial η2 = 0.241, but not in the
ERW group, F(1.44,40.21) = 2.11, p = 0.147, partial η2 = 0.070; in the former, subcutaneous fat mass was
significantly lower at 8 weeks than at baseline (Mdiff = 0.996, SE = 0.263 kg, p = 0.003).
Both the right and left mean CAVI decreased with time in the ERW group, while neither displayed
a significant difference in the primary effect for either time point, F(1.45,73.80) = 0.36, p = 0.627, partial
η2 = 0.007 (Rt), F(1.44,73.30) = 0.38, p = 0.444, partial η2 = 0.014 (Lt); or group, F(1,51) = 0.11, p = 0.738,
partial η2 = 0.002 (Rt), F(1,51) = 0.32, p = 0.577, partial η2 = 0.006 (Lt). Similarly, no significant difference
was observed in the interaction between the group and time, F(1.45,73.80) = 0.38, p = 0.615 partial
η2 = 0.007 (Rt), F(1.44,73.30) = 0.29, p = 0.677, partial η2 = 0.006 (Lt) (Table 4 and Table S4).
Regarding the time domain parameters of HRV, PSI decreased with time, whereas TP increased
through the study period in the ERW group. However, none of the HRV parameters differed significantly
in terms of the effect of time, the effect of the group, or the interaction between the group and time
(Table 4 and Table S4).
All parameters of PhA were not significantly different in the effect of the intervention, and the
interaction between the group and time (Table 4 and Table S4).
3.5. Effect of Treatment on the Secondary Outcome Variables, BEPSI-K, BFI, FSS, and SF-36 Score
Herein, although the BEPSI-K score tended to decrease with time in the ERW group, the interaction
between group and time did not significantly influence the BEPSI-K score (F(2,102) = 0.68, p = 0.511,
partial η2 = 0.013); similarly, the mean BEPSI-K score did not significantly differ between the two
groups (F(1,51) = 0.01, p = 0.907, partial η2 < 0.001, or at different time points, F(2, 102) = 0.60, p = 0.553,
partial η2 = 0.012) (Table 5 and Table S5).
The BFI global score, BFI severity score, and BFI interference score were significantly influenced
by the treatment duration, [F(2,102) = 4.28, p = 0.016, partial η2 = 0.077], [F(2,102) = 3.11, p = 0.049,
partial η2 = 0.057], and [F(2,102) = 3.72, p = 0.028, partial η2 = 0.068], respectively; however, they were
not significantly influenced by the group ([F(1,51) < 0.01, p = 0.964, partial η2 < 0.001], [F(1,51) = 0.33,
p = 0.566, partial η2 = 0.007], and [F(1,51) = 0.04, p = 0.845, partial η2 = 0.001], respectively) or by the
interaction between the group and time ([F(2,102) = 0.11, p = 0.901, partial η2 = 0.002], [F(2,102) = 0.05,
p = 0.956, partial η2 = 0.001], and [F(2,102) = 0.11, p = 0.895, partial η2 = 0.002], respectively) (Table 5
and Table S5).
The FSS score was lower at 4 and 8 weeks than at baseline in both groups; however, the effect of
the groups (F(1,51) = 0.01, p = 0.928, partial η2 < 0.001), the effect of time (F(1.74,88.48) = 1.83, p = 0.172,
partial η2 = 0.035), and the interaction between the group and time (F(1.74,88.48) = 0.68, p = 0.489,
partial η2 = 0.013) did not significantly influence the FSS score (Table 5 and Table S5).
The group, duration of treatment, and interaction between the group and time did not significantly
influence the scores of every item of SF-36 (Table 5 and Table S5).
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(n = 24) p
Outcome Variables Means ± SD Means ± SD Time Group Time * Group
Fat Mass-Total (kg)
Baseline 16.21 ± 4.88 17.30 ± 5.03
4 weeks 16.18 ± 5.00 16.55 ± 4.90 0.000 0.678 0.041
8 weeks 15.86 ± 4.86 16.10 ± 5.31
Fat Mass-Visceral (kg)
Baseline 1.86 ± 0.96 2.00 ± 0.95
4 weeks 1.87 ± 1.00 1.87 ± 0.82 0.000 0.846 0.027
8 weeks 1.79 ± 0.94 1.80 ± 0.93
Fat Mass-Subcutaneous (kg)
Baseline 14.36 ± 3.96 15.30 ± 4.12
4 weeks 14.30 ± 4.04 14.69 ± 4.11 0.000 0.644 0.047
8 weeks 14.07 ± 3.96 14.30 ± 4.41
CAVI-Rt
Baseline 6.44 ± 0.80 6.36 ± 1.06
4 weeks 6.32 ± 0.80 6.36 ± 0.73 0.627 0.738 0.615
8 weeks 6.18 ± 0.69 6.36 ± 0.86
CAVI-Lt
Baseline 6.52 ± 0.77 6.48 ± 1.11
4 weeks 6.38 ± 0.83 6.48 ± 0.76 0.444 0.577 0.677
8 weeks 6.23 ± 0.69 6.42 ± 0.81
HRV-PSI
Baseline 71.92 ± 81.46 52.85 ± 31.23
4 weeks 71.54 ± 59.39 54.99 ± 33.62 0.825 0.182 0.765
8 weeks 63.09 ± 41.19 54.68 ± 38.06
HRV-TP (ms2)
Baseline 913.43 ± 613.60 1071.63 ± 876.97
4 weeks 985.86 ± 1030.49 1041.21 ± 1223.80 0.502 0.795 0.851
8 weeks 1185.43 ± 1570.90 1115.73 ± 973.82
HRV-LF/HF
Baseline 1.52 ± 1.30 2.01 ± 2.14
4 weeks 1.64 ± 1.41 1.64 ± 1.79 0.629 0.958 0.197
8 weeks 2.19 ± 2.43 1.64 ± 1.34
Phase Angle (◦ )
Baseline 5.89 ± 0.85 5.83 ± 0.85
4 weeks 5.63 ± 0.75 5.67 ± 0.78 0.000 0.952 0.566
8 weeks 5.62 ± 0.67 5.60 ± 0.84
Note: * Interaction between Time and the Group. Abbreviations: CAVI, cardio-ankle vascular index; HRV, heart rate
variability; PSI, physical stress index; TP, total power; LF, low frequency; HF, high frequency.
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(n = 24) p
Outcome Variables Mean ± SD Mean ± SD Time Group Time * Group
BEPSI-K
Baseline 1.82 ± 0.65 1.73 ± 0.51
4 weeks 1.71 ± 0.72 1.73 ± 0.51 0.553 0.907 0.511
8 weeks 1.76 ± 0.73 1.78 ± 0.56
BFI
BFI Global
Baseline 4.14 ± 2.09 4.01 ± 2.27
4 weeks 3.60 ± 1.98 3.56 ± 2.09 0.016 0.964 0.901
8 weeks 3.28 ± 2.29 3.38 ± 2.28
BFI Severity
Baseline 5.69 ± 2.06 5.36 ± 2.45
4 weeks 5.49 ± 1.77 5.14 ± 2.28 0.049 0.566 0.956
8 weeks 4.90 ± 2.32 4.71 ± 2.40
BFI Interference
Baseline 3.36 ± 2.39 3.33 ± 2.38
4 weeks 2.66 ± 2.37 2.76 ± 2.30 0.028 0.845 0.895
8 weeks 2.47 ± 2.46 2.72 ± 2.41
FSS
Baseline 3.58 ± 1.58 3.65 ± 1.68
4 weeks 3.15 ± 1.53 3.40 ± 1.67 0.172 0.928 0.489
8 weeks 3.39 ± 1.81 3.17 ± 1.65
Note: * Interaction between Time and the Group. Abbreviations: BEPSI-K, Brief Encounter Psychosocial
Instrument-Korean version; BFI, brief fatigue inventory; FSS, fatigue severity scale; SF-36, 36-item short-form survey.
4. Discussion
This study was the first randomized, double-blind, placebo-controlled trial to assess the outcomes
of specific lifestyle modification, namely drinking ERW for eight weeks at the workplace, in healthy
adults. The assessment was based on a comprehensive evaluation of biomarkers of oxidative stress,
encompassing reactive oxygen metabolites, total antioxidant potential, oxidative stress-induced
damaged macromolecules (lipid, DNA, and protein), and antioxidant enzymes as primary outcomes,
as well as various health-related indices of altered medical conditions resulting from oxidative stress
as secondary outcomes. Diverse biochemical parameters and fat mass were measured to assess the
effect of ERW on glucose and lipid metabolism as well as on body composition. To assess effects on
arterial stiffness, the cardio-ankle vascular indices were measured. HRV was measured to evaluate the
change in cardiac autonomic function after drinking ERW, and phase angle was measured as an index
of cellular health. The effects of drinking ERW on stress, fatigue, and quality of life were assessed by
using BEPSI-K, BFI and FSS, and SF-36 questionnaires.
The majority of healthy adults spend most of their waking hours at work, so the workplace appears
to be the ideal place to adopt a healthy lifestyle. Hence, health promotion programs adopting lifestyle
modifications at the workplace are being implemented in several countries. There have been several
randomized clinical trials assessing the effects of healthy behaviors at the workplace [39–42], with some
meeting their primary endpoints, whereas others not meeting their primary endpoints. Meanwhile,
such trials have raised questions regarding sustainability, affordability, and cost-effectiveness [38,43].
Successful and sustainable programs based on lifestyle modifications must be accessible [81], affordable,
effective, and equitable to all individuals without discrimination or disparities [43,82,83].
Although there are diverse biomarkers available for the estimation of the status of oxidative
stress, there continues to be a lack of consensus on which biomarkers are best suited for measuring
redox states. Hence, usually, several biomarkers are measured together, including free radicals, ROS,
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oxidative stress-induced damaged macromolecules, antioxidant capacity, and antioxidant enzymes for
antioxidant potential. Although it would be ideal to directly measure reactive species [84], this approach
was excluded from our study because of their high reactivity and short half-life [84].
The BAP and d-ROMs tests have been widely used as biomarkers measuring antioxidant activity
and oxidative stress as a whole [52,55,84]. In this study, both biomarkers demonstrated a significant
association between the group and timely intervention, indicating that eight weeks of consuming ERW
may prove effective in both reducing oxidative stress and increasing antioxidant potential compared
to drinking MW. Electrolysis of water produces hydrogen molecules and hydrogen atoms (active
hydrogen) in the vicinity of the platinum plate at the cathode [12], both of which have been shown to
contribute to reduced oxidative stress by scavenging ROS [12]. Additionally, platinum nanoparticles
(PtNPs) and PtNP-hybrids formed near the cathode seem to scavenge ROS, including superoxide
radicals, hydroxyl radicals, and hydrogen peroxide [12]. The MDA, OHdG, and oxLDL biomarkers
were measured to evaluate the oxidation of proteins, DNA, and lipids by free radicals, respectively.
Regarding MDA and OHdG, treatment revealed a significant difference in the mean concentration of
MDA and OHdG at different time points but did not exhibit significant interaction between the group
and timely intervention. The concentration of MDA and 8-OHdG in this study was measured using
spot urine. However, there has been a controversy over whether to normalize biomarkers in urine
with the concentration of urinary creatinine (µCr) since the rate of excretion of urinary creatinine may
change according to age, sex, exercise, diet, stress, muscle mass, and stress [85]. Approximately 20% of
the subjects were exercising at various intensities during the study period, so we chose not to perform
normalization in this study, considering the potential effect on the concentration of urine creatinine.
It is known that ROS may change the surface charge of NK cells to negative, thereby disturbing the
attachment of NK cells to target cancer cells, which are usually anionic [86]. pH-centered cancer care
is attracting more and more attention in the field of oncology [87], and numerous studies have been
attempted to modify the alkaline intracellular and acidic extracellular microenvironment of cancer
cells [87,88]. The activity of NK cells showed a great increase from baseline (949.0 ± 810.68) to 4 weeks
(1943.5 ± 1109.2) and 8 weeks (1814.2 ± 1091.8) in both the ERW and MW groups in this study. We may,
therefore, cautiously postulate from the perspective of nutritional immunology that drinking ERW may
be a potential candidate for cancer prevention [89–91]. Most of the tested biochemistry parameters did
not demonstrate a statistical difference in the interaction between time and group even though several
parameters related to glucose metabolism (AGE, insulin, HOMA-IR, and cortisol) showed a tendency
to decrease at 4 and 8 weeks compared to those at baseline. Besides, the ion concentrations of ERW and
MW are possibly different, and these differences might have also influenced the observed differences
in biochemical parameters before and after drinking ERW and MW. The lack of ion concentration
measurement may be considered as a limitation of this study.
Although our results showed a decreased tendency in BEPSI-K, BFI, and FSS scores at 4 and
8 weeks of intervention compared to those at baseline, the interaction between the group and time did
not reach statistical significance. Furthermore, each SF-36 item did not exhibit significant differences
over time between the two groups.
Notably, most biomarkers of oxidative stress and health-related indices showed less improvement
during the last 4 weeks compared to the first 4 weeks, and this effect may be attributed to the observed
difference in the average intake of water between the two periods (1481 ± 78 vs. 1311 ± 201, p < 0.001).
For instance, reduced intake of water due to busier schedules during the last 4 weeks might have
affected the differences shown in outcome variables between the 4 and 8 weeks. There was one study
related to the intake of blueberry, showing a blunted improvement of biomarkers of oxidative stress
later in the intervention. One of the diverse interpretations suggested for this finding was that there
might have been an acclimation leading to reduced oxidative damage over time [92]. More study
subjects and more extended study periods are needed to verify the acclimation effect on oxidative
biomarkers [92]. Hence, to more precisely characterize the clinical and statistical significance of the
effect elicited by drinking ERW on various biochemical parameters, stress, fatigue, and quality of
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life in terms of lifestyle modification at the workplace, studies involving a larger sample size of
participants over a more extended study period, with efforts to reduce the number of participant
dropouts, are warranted.
In body composition analysis, total, visceral, and subcutaneous fat mass showed a more significant
decrease over time in the ERW relative to the MW group. ERW might have directly induced
lipolysis in adipocytes, downregulated the expression of transcription factors in the adipogenesis
pathway, or reduced accumulation of lipids by affecting the expression of genes, such as fatty acid
synthase (FAS), lipoprotein lipase (LPL), or hormone-sensitive lipase (HSL) during the differentiation
of preadipocytes [93–95]. Additionally, ERW might have influenced the production of leptin or
adiponectin [94,96], which would have accounted for the observed fat mass reduction. A colonization
pattern of microbiota has been known to be one of the contributing factors of obesity, while a higher
ratio of Firmicutes over Bacteroidetes has been demonstrated as a pattern commonly seen in obese
people [97–100]. One study showed that anaerobes and aerobes grow at environments of different
oxidation-reduction potential (ORP), thus drinking ERW might favor the growth of anaerobes [101].
On the other hand, the ORP is an important component showing the antioxidant potential of the
reduced water. In a previous study comparing the ORP of reduced water with different pH, an ERW
sample with a pH close to 10 showed considerably higher negative ORP value in vitro compared to
ERW with a pH of 9.5 [102]. In future studies, it is recommended to compare ERW with different
pH and ORP values to find out the best outcome in terms of antioxidant potential. Platinum coated
on titanium electrode plates is already commonly used and known to be effective for electrolysis;
further research on new materials, such as Nickel-Cobalt-Titanium alloy, that may increase ORP and
the cost-effectiveness [103] will allow more individuals to benefit from drinking ERW.
5. Conclusions
This study was an RCT employed to determine the effects of ERW on biomarkers of oxidative
stress and health-related indices in healthy adults. Drinking of ERW improved the major biomarkers
of oxidative stress and body fat mass. Significant interactions were observed between the intervention
and time on d-ROMs, BAP, and fat mass. Hence, drinking ERW on a daily basis may be effective in
the reduction of oxidative stress and increase of oxidant potential, as well as in the decrease of total
body, visceral, and subcutaneous fat mass. However, additional research participants with a more
extended study period as well as analysis of the ionic concentrations of ERW and MW are needed in
future studies to definitively support the adoption of drinking ERW at the workplace as an effective,
equitable, accessible, sustainable, and innovatively simple lifestyle modification for health promotion.
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